Best response to nivolumab (RECIST v 1.1) based on RCC histology
| Histology | N | PR | SD | PD | Non-evaluable |
|---|---|---|---|---|---|
| Papillary | 16 | 2 (14%) | 3 (21%) | 9 (64%) | 2 |
| Unclassified | 14 | 4 (36%) | 3 (27%) | 4 (36%) | 3 |
| Chromophobe | 5 | 0 (0%) | 3 (75%) | 1 (25%) | 1 |
| Collecting Duct | 4 | 1 (25%) | 0 (0%) | 3 (75%) | 0 |
| MTSCC | 1 | 0 (0%) | 1 (100%) | 0 (0%) | 0 |
| Translocation | 1 | 0 (0%) | 0 (0%) | 1 (100%) | 0 |
| All Histologies | 41 | 7 (20%) | 10 (29%) | 18 (51%) | 6 |
No complete responses (CRs) were observed in this study
For some histologies total percentages do not add up to 100% due to rounding
Abbreviations: RECIST Response Criteria in Solid Tumors, PR Partial Response, SD Stable Disease, PD Progressive Disease, MTSCC Mucinous Tubular and Spindle Cell Carcinoma